Effect of LB-SCS and gentamicin treatments on the viability of C1845 bacteria.
| Treatment | Viable bacteria† (log cfu/ml) | Viable adhering bacteria‡ (log cfu/ml) |
|---|---|---|
| †Antimicrobial activity of LB-SCS in vitro. Colony count assay was performed after incubating 1 ml of phosphate buffered saline containing C1845 bacteria (108 cfu/ml) with 1 ml of MRS or LB-SCS at 37°C for three hours. | ||
| ‡Antimicrobial activity of LB-SCS in C1845 preinfected Caco-2/TC7 cells. After infection of Caco-2/TC7 cells (108cfu/ml) with C1845 bacteria for three hours, cells were subjected to MRS, LB-SCS, or gentamicin treatment for one hour at 37°C. Results are presented as mean (SEM) obtained from 3–4 experiments, each in triplicate. | ||
| Statistical analysis was performed using a Student's t test: **p<0.01 compared with control uninfected cells. | ||
| LB-SCS, spent culture supernatant of Lactobacillusacidophilus LB culture; MRS broth, De Man, Rogosa, Sharpe broth; ND, not determined | ||
| Control | 8.43 (0.2) | 7.25 (0.3) |
| LB-SCS | 7.72 (0.3) | ND |
| LB-SCS 0.5-fold concentrate | 7.95 (0.3) | ND |
| LB-SCS 2.0-fold concentrate | 5.69 (0.2)** | 4.20 (0.3)** |
| LB-SCS 2.5-fold concentrate | 3.72 (0.2)** | ND |
| MRS | 7.85 (0.2) | ND |
| MRS 2.0-fold concentrate | 7.78 (0.3) | 5.93 (0.4)** |
| MRS 2.5-fold concentrate | 6.18 (0.2)** | ND |
| Gentamicin 50 μg/ml | ND | 6.42 (0.3)** |
| Gentamicin 100 μg/ml | ND | 4.48 (0.3)** |
| Gentamicin 200 μg/ml | ND | 3.98 (0.2)** |